Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the safety, tolerability, and immunogenicity of re-dosing at 6 months with an 8-consecutive day series of otelixizumab intravenous (IV) infusions in adult subjects with newly diagnosed T1DM.
Critère d'inclusion
- Autoimmune new onset type 1 diabetes mellitus